LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO will discuss BioSante’s recently granted special protocol assessment (SPA) for the Phase III development of LibiGel (testosterone gel) in the treatment of female sexual dysfunction (FSD), at the BIO CEO and Investor Conference at the Waldorf Astoria in New York City. Mr. Simes will present on February 11, 2008 at 2:45 p.m. local time. A corporate update and overview also will be presented.
